Eltrombopag treatment for thrombocytopenia in myelodysplastic syndromes: differences between responding and non-responding patients-a pilot study.

Castelli R; Manetti R; Sechi GL; Deliliers GL; Gidaro A

doi:10.1007/s11739-024-03804-3

Eltrombopag treatment for thrombocytopenia in myelodysplastic syndromes: differences between responding and non-responding patients-a pilot study.

Affiliations

1. Dipartimento di Medicina, Chirurgia e Farmacia Università degli Studi di Sassari e Azienda Ospedaliera, Universitaria di Sassari, Viale San Pietro 8, Sassari, Italy.
Authors
Castelli R¹
Manetti R¹
Sechi GL¹
(3 authors)
2. Fondazione Matarelli Milano, Milan, Italy.
Authors
Deliliers GL²
(1 author)
3. Department of Biomedical and Clinical Sciences, "Luigi Sacco", University of Milan, Luigi Sacco Hospital, Milan, Italy.
Authors
Gidaro A³
(1 author)

ORCIDs linked to this article

Castelli R | 0009-0003-6756-9074

Internal and Emergency Medicine, 31 Oct 2024,
https://doi.org/10.1007/s11739-024-03804-3 PMID: 39480602

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1007/s11739-024-03804-3

References

Articles referenced by this article (5)

Immune Thrombocytopenia.
Cooper N, Ghanima W
N Engl J Med, (10):945-955 2019
MED: 31483965
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R, Leveque J
Cancer, (9):1705-1714 2007
MED: 17366593
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM
Cancer, (12):1838-1846 2014
MED: 24706489
European consensus on grading bone marrow fibrosis and assessment of cellularity.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A
Haematologica, (8):1128-1132 2005
MED: 16079113
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisa E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Ianni G, Russo E, Castelli A, [...] Latagliata R
J Clin Oncol, (28):4486-4496 2023
MED: 37294914

Search life-sciences literature (45,104,931 articles, preprints and more)

Eltrombopag treatment for thrombocytopenia in myelodysplastic syndromes: differences between responding and non-responding patients-a pilot study.

Affiliations

Authors

Authors

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Immune Thrombocytopenia.

The incidence and impact of thrombocytopenia in myelodysplastic syndromes.

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.

European consensus on grading bone marrow fibrosis and assessment of cellularity.

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).

Similar Articles

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.

Eltrombopag for treatment of thrombocytopenia-associated disorders.

Partnerships & funding

Similar Articles

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Lancet Haematol, 4(3):e127-e136, 03 Feb 2017

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Lancet Haematol, 2(10):e417-26, 01 Oct 2015

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Eur J Haematol, 93(5):439-445, 14 Jun 2014

Eltrombopag for treatment of thrombocytopenia-associated disorders.
Expert Opin Pharmacother, 16(14):2243-2256, 01 Jan 2015

Search life-sciences literature (45,104,931 articles, preprints and more)

Eltrombopag treatment for thrombocytopenia in myelodysplastic syndromes: differences between responding and non-responding patients-a pilot study.

Author information

Affiliations

Authors

Authors

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Similar Articles

Partnerships & funding